Dentists in Sneads Ferry, NC Accepting Medicare
7 Dentists found. Showing 1 - 7
 Dr. Nicholas Dean Lenker, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 1112 Nc Highway 210, Sneads Ferry, NC 28460 Phone: 910-741-1555 |
William Miller, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 105 Prescott Cir, Sneads Ferry, NC 28460 Phone: 352-448-6474 |
 Belinda Phan, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 1112 Nc Highway 210, Sneads Ferry, NC 28460 Phone: 910-741-1555 |
Dr. Amanda Louise Gill, DMD Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1112 Nc Highway 210, Sneads Ferry, NC 28460 Phone: 910-741-1555 |
Michael Garret Schut, DMD Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 1319 Nc Highway 210, Sneads Ferry, NC 28460 Phone: 910-327-2248 |
Steven William Smith Jr., D.D.S. Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 1112 Nc Highway 210, Sneads Ferry, NC 28460 Phone: 910-741-1555 Fax: 910-741-4051 |
Dr. Mallory Dahn Kuiper, D.D.S. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1112 Nc Highway 210, Sneads Ferry, NC 28460 Phone: 910-741-1555 |
News Archive
Thickening of arterial walls causes branch retinal vein occlusion
Branch retinal vein occlusion - blockage of the blood vessels that channel blood from the retina - is a common eye disease. A type of blood clot in the eye, the disease causes reduced vision, and people with the disease also typically have an increased risk of hypertension, diabetes and other serious conditions. A young scientist from the University of Copenhagen has made a significant contribution to finding the cause of the disease.
S1 registration statement of Kraig Biocraft Laboratories declared effective
Kraig Biocraft Laboratories, Inc., a biotechnology company focused on the development of commercially significant high performance polymers and technical fiber including spider silk, is very pleased to announce that its S1 registration statement has been declared effective. The Company filed the S1 registration statement in October of 2009 and has been working diligently over the last nine months to obtain this clearance.
Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin
Seattle Genetics, Inc. today announced that it has completed enrollment of its pivotal clinical trial of brentuximab vedotin (SGN-35) for relapsed and refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30 utilizing the company's proprietary ADC technology.
Viruses from stool can help fight obesity and type 2 diabetes
Obese mice with unhealthy lifestyles gain significantly less weight and avoid type 2 diabetes when they receive viruses transplanted from the stool of lean mice. These are the findings of a new University of Copenhagen study.
68Ga-pentixafor PET imaging is an effective diagnostic tool for CNS B-cell lymphoma
Positron emission tomography (PET) imaging with 68Ga-pentixafor is an effective diagnostic tool for central nervous system (CNS) B-cell lymphoma, according to a proof-of-concept study published in the December issue of The Journal of Nuclear Medicine.
› Verified 5 days ago
Counselors
Pharmacists
Dentists
Clinical Social Workers
Occupational Therapists